期刊文献+

抗重组高效抗肿瘤抗病毒蛋白抗药抗体ELISA检测方法的建立及应用

Validation and its application of an ELISA method for the detection of anti-drug antibody against recombinant potent anti-tumor and anti-virus protein in patient sera
原文传递
导出
摘要 目的:建立受试者血清中重组高效抗肿瘤抗病毒蛋白抗药抗体的检测方法,考察用药后不同组别受试者的抗药抗体产生情况。方法:首先建立了检测血清中抗药抗体ELISA方法并进行了方法学的验证;然后筛选了3个给药组血清样本中的抗药抗体,用结果为阳性的受试者血清最大稀释倍数表示抗药抗体的滴度。结果:该ELISA方法检测乐复能血清抗药抗体的特异性好,检测限为204 ng·mL-1,高、中、低及阴性样本批内、批间重复性CV值均小于6%,达到常规ELISA的标准。10μg连续给药组7例受试者首次用药3周后有3例产生抗体,用药5周后均产生抗体;10μg隔日给药组6例受试者首次用药4周后均产生抗体;20μg隔日连续给药组10例受试者首次用药2周后有1例产生抗体,用药4周后8例产生抗体,用药6周后9例产生抗体。结论:建立了重组高效抗肿瘤抗病毒蛋白免疫原性的ELISA检测方法。首次用药4周后3个组的抗药抗体阳性率达到高值,组别之间无明显差别。比较而言,第3组(20μg隔日给药)的抗药抗体滴度较低。 Objective: To establish a method to detect anti-drug antibody in the sera of HBeAg positive patients injected with a recombinant potent anti-tumor and anti-virus protein. Methods: The established ELISA method was validated,and used to screen the anti-drug antibody in the serum samples from the three groups. The largest dilution was determined as the titer of anti-drug antibody in each positive sample. Results: The established ELISA method was specific to detect the anti-drug antibody in the serum with the detection limit of 204 ng·mL^-1. All the intra-and inter-batch variation coefficients of all detected concentrations were below 6%,fitting the standard of conventional ELISA. In the 10 μg qd group,3 of 7 subjects emerged anti-drug antibodies at 3 weeks,while all subjects emerged anti-drug antibodies at 5 weeks after the first injection. In the 10 μg qod group,all the 6 subjects emerged anti-drug antibodies at 4 weeks. In the 20 μg qod group,1 of 10 subjects produced antibodies at 2 weeks,and 8 subjects produced antibodies at 4 weeks,while 9 subjects produced antibodies at 6 weeks after the first injection. Conclusion: We have established an ELISA method to detect the antibody against a recombinant potent antitumor and anti-virus protein in the patients injected with this protein. The three groups reached high value of antidrug antibodies at 4 weeks after injection without significant difference between groups. In comparison,the third group( 20 μg qod) has a lower anti-drug antibody activity.
出处 《中国新药杂志》 CAS CSCD 北大核心 2014年第20期2377-2381,共5页 Chinese Journal of New Drugs
基金 国家"重大新药创制"科技重大专项(2011ZX09101-008-05)
关键词 重组高效抗肿瘤抗病毒蛋白注射液 抗药抗体 免疫原性 recombinant potent anti-tumor and anti-virus protein immunogenicity antidrug antibody
  • 相关文献

参考文献10

  • 1吕秋军.生物技术药物免疫原性的评价及面临的挑战[J].中国新药杂志,2007,16(3):181-188. 被引量:24
  • 2KIRSHNER S. Assay Development for Immunogenicity Testing of Therapeutic Proteins[ EB/OL]. (2009 - 12). http://www, fda. gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm192750, pdf.
  • 3CROWTHER JR. The ELISA guidebook: methods in molecular biology[ M]. New Jersey: Humana Press, 2001: 206.
  • 4王豪,常锦红.抗干扰素抗体[J].国外医学(流行病学.传染病学分册),1997,24(2):53-56. 被引量:3
  • 5陈雪静,刘晓志,常亮.抗体药物免疫原性的研究进展[J].中国生物制品学杂志,2013,26(7):1043-1046. 被引量:3
  • 6薛秀霞.治疗用生物大分子免疫原性的研究进展[J].齐鲁药事,2012,31(3):174-176. 被引量:8
  • 7HOLGATE RG, BAKER MP. Circumventing immunogenicity in the development of therapeutic antibodies [ J ]. IDrugs, 2009,12 (4) :233 -237.
  • 8ALMAGRO JC, FRANSSON J. Humanization of antibodies [ J ]. Front Biosci ,2008,13 ( 1 ) : 1619 - 1633.
  • 9LOK ASF, LAI CL, LEUNG EKY, et al. Interferon antibodies may negate the antiviral effects of recombinant a-Interferon treat- ment in patients with chronic hepatitis B virus infection[ J]. Hep- atology, 1990,12 ( 6 ) : 1266 - 1270.
  • 10PORRES JC, CARRENO V, RUIZ M, et al. Interferon antibod- ies in patients with chronic HBV infection treated with recombi- nant interferon[J]. J Hepatol, 1989, 8(3): 351-357.

二级参考文献75

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部